TY - JOUR
T1 - Diet-Induced Alteration of Microbiota and Development of Obesity, Nonalcoholic Fatty Liver Disease, and Diabetes
T2 - Study Protocol of a Prospective Study
AU - Uittenbogaart, Martine
AU - Leclercq, Wouter K. G.
AU - Bonouvrie, Danielle
AU - Romeijn, Marleen M.
AU - Luijten, Arijan A. P. M.
AU - Damink, Steven W. M. Olde
AU - van Dielen, Francois M. H.
AU - Rensen, Sander S.
N1 - Publisher Copyright:
© Martine Uittenbogaart, Wouter KG Leclercq, Danielle Bonouvrie, Marleen M Romeijn, Arijan APM Luijten, Steven WM Olde Damink, Francois MH van Dielen, Sander S Rensen. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 09.06.2019.
PY - 2019/6
Y1 - 2019/6
N2 - Background: Development of obesity and obesity-related diseases, such as type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD), is associated with altered gut microbiota composition. The aim of this study is to investigate associations among dietary compounds, intestinal cell function, and gut microbiota composition. We hypothesize that dietary lipid intake is associated with Paneth cell and goblet cell properties that affect gut microbiota composition.Objective: The primary objective of this study is to determine whether a difference in dietary intake is associated with a difference in intestinal mucin-2 expression and gut microbiota composition.Methods: This is a single-center prospective study, including 1 obese group undergoing laparoscopic Roux-en-y gastric bypass and 2 lean control groups undergoing either laparoscopic cholecystectomy or upper gastrointestinal endoscopy (n=228). During laparoscopy, biopsies will be taken of visceral fat (omentum majus), liver, muscle tissue of the abdominal wall, and subcutaneous fat. In the obese group, a small segment of the jejunum will be collected for analysis, which will be compared with an endoscopically derived jejunal biopsy from the upper gastrointestinal endoscopy control group. Stool samples for microbiota profiling will be collected at baseline and 1 year after surgery. Primary outcomes are fecal microbiota composition and mucus characteristics. Secondary outcomes include Paneth cell phenotype, body weight, diet composition, glucose tolerance, resolution of comorbidities, and weight loss 1 year after surgery.Results: This trial is currently open for recruitment. The anticipated completion date is December 2019.Conclusions: The Diet-Induced Alteration of Microbiota and Development of Obesity, NAFLD, and Diabetes study will improve insight into the pathophysiology of obesity and its associated metabolic disorders. Better understanding of weight loss failure and weight regain following bariatric surgery might also behold new therapeutic opportunities for obesity and obesity-related comorbidities.
AB - Background: Development of obesity and obesity-related diseases, such as type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD), is associated with altered gut microbiota composition. The aim of this study is to investigate associations among dietary compounds, intestinal cell function, and gut microbiota composition. We hypothesize that dietary lipid intake is associated with Paneth cell and goblet cell properties that affect gut microbiota composition.Objective: The primary objective of this study is to determine whether a difference in dietary intake is associated with a difference in intestinal mucin-2 expression and gut microbiota composition.Methods: This is a single-center prospective study, including 1 obese group undergoing laparoscopic Roux-en-y gastric bypass and 2 lean control groups undergoing either laparoscopic cholecystectomy or upper gastrointestinal endoscopy (n=228). During laparoscopy, biopsies will be taken of visceral fat (omentum majus), liver, muscle tissue of the abdominal wall, and subcutaneous fat. In the obese group, a small segment of the jejunum will be collected for analysis, which will be compared with an endoscopically derived jejunal biopsy from the upper gastrointestinal endoscopy control group. Stool samples for microbiota profiling will be collected at baseline and 1 year after surgery. Primary outcomes are fecal microbiota composition and mucus characteristics. Secondary outcomes include Paneth cell phenotype, body weight, diet composition, glucose tolerance, resolution of comorbidities, and weight loss 1 year after surgery.Results: This trial is currently open for recruitment. The anticipated completion date is December 2019.Conclusions: The Diet-Induced Alteration of Microbiota and Development of Obesity, NAFLD, and Diabetes study will improve insight into the pathophysiology of obesity and its associated metabolic disorders. Better understanding of weight loss failure and weight regain following bariatric surgery might also behold new therapeutic opportunities for obesity and obesity-related comorbidities.
KW - microbiota
KW - type 2 diabetes
KW - obesity
KW - NAFLD
KW - gastric bypass
KW - GUT MICROBIOTA
KW - INTESTINAL MICROBIOTA
U2 - 10.2196/11553
DO - 10.2196/11553
M3 - Article
C2 - 31219051
SN - 1929-0748
VL - 8
SP - 1
EP - 6
JO - JMIR Research Protocols
JF - JMIR Research Protocols
IS - 6
M1 - 11553
ER -